Long-term use of rosuvastatin: A critical risk benefit appraisal and comparison with other antihyperlipidemics

Drug, Healthcare and Patient Safety

Volumn 1, Issue 1, 2009, Pages 25-33

  Calza, Leonardo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

HMG CoA reductase; LDL cholesterol; Pharmacokinetics; Safety; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CREATINE KINASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIGOXIN; FOSAMPRENAVIR; GLYCOPROTEIN P; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; ITRACONAZOLE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; DRUG WITHDRAWAL; ENZYME INHIBITOR INTERACTION; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IC 50; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; PAIN; PHARYNGITIS; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 72449181884     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s4928     Document Type: Review

References (49)

1. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239.
2. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction. Circulation. 2001;103:38-44.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial inferction with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
5. Downs JR, Clearfield M, Wels S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
6. Schwartz GG, Olsson AG, Ezkowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. JAMA. 2001;285:1711-1716.
7. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
8. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol. 1998;81:582-587.
9. White CM. An evaluation of CYP3A4 drug interactions with HMG CoA reductase inhibitors. Formulary. 2000;35:343-352.
10. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42:963-970.
11. White CM, Chow MS. A review of HMG CoA reductase inhibitors. US Pharmacist. 1998;23:HS19-HS28.
12. Watanabe M, Koike H, Ishiba T, Okada T, Seo S, Hirai K. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6 heptenoates, a novel series of MHG CoA reductase inhibitors. Bioorg Med Chem. 1997;5:437-444.
13. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG CoA reductase. Science. 2001;292:1160-1164.
14. Smith D, Davidson R, Bloor S, et al. Pharmacological properties of ZD4522: a new HMG CoA reductase inhibitor. Atherosclerosis. 2000;151:39.
15. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis. 2000;151:41.
16. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(Suppl 5 A):28B-32B.
17. Negre-Aminou P, Van Vliet AK, Van Erck M, et al. Inhibition of proliferation of human smooth muscle cells by various HMG CoA reductase inhibitors: comparison with other human cell types. Biochemica et Biophysica Acta. 1997;1345:259-268.
18. Warwick MJ, Dane AL, Raza A, Scheneck DW. Single and multiple-dose pharmacokinetics and safety of the new HMG CoA reductase inhibitor ZD4522. Atherosclerosis. 2000;151:39.
19. Mcormick AD, McKillop D, Butters CJ, et al. ZD4522- an HMG CoA reductase inhibitor free metabolically mediated drug interactions: metabolic studies in human in vitro systems. J Clin Pharmacol. 2000;40:1055.
20. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG CoA reductase inhibitors. Ann Pharmacother. 2001;35:1096-1107.
21. Wang E, Casciano CN, Clement RP, Johnson WW. HMG CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001;18:800-806.
22. Boyd RA, Stern RH, Stewart BH. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000;40:91-98.
23. Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2003;73:322-329.
24. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res. 2008;6:572-578.
25. Busti AJ, Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008;51:605-610.
26. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug-drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570-578.
27. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88:504-508.
28. Stein E, Strutt KL, Miller E, Southworth H. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2001;37(Suppl):292A.
29. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
30. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Therap. 2004;26:1388-1399.
31. Ai M, Otokozawa S, Asztalos BF, et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol. 2008;101:315-318.
32. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144:1044-1051.
33. Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J. 2002;144:1036-1043.
34. Julius U, Dittrich M, Pietzsch J. Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance. Int J Clin Pract. 2007;61:1798-1804.
35. Rizzo M, Berneis K, Spinas GA, Rini GB, Kapur NK. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance? Int J Clin Pract. 2009;63:478-485.
36. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2280-2282.
37. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175-1182.
38. Petition to the FDA to issue strong warnings about the potential for certain cholesterol lowering drugs to cause potentially life-threatening muscle damage. Retrieved from http:/www.citizen.org/publications/release.cfm?ID=7051.
39. Staffa J. Letter to the editor. N Engl J Med. 2002;346:539-540.
40. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565-569.
41. Shepherd J, Hunninghake D, Harris S, Hutchinson H, Pears J. A review of the safety profile of rosuvastatin in an international phase II/III clinical trial program. Paper presented at the XIV International Symposium on Drugs Affecting Lipid Metabolism, New York, September 2001.
42. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48000 initiators of statin therapy. Pharmacoepidemiol Drug Saf. 2006;15:444-453.
43. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology. 2007;107:433-443.
44. Kasliwai R, Wilton LV, Cornelius V, Aurich-Barrera B, Shakir SA. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11680 patients. Drug Saf. 2007;30:157-170.
45. Riccioni G. Statins and carotid intima-media thickness reduction: an up-do-date review. Curr Med Chem. 2009;16:1799-1805.
46. Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Muller GA. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol. 2009 Feb 26:1-5. [Epub ahead of print].
47. Montecucco F, Burger F, Pelli G, et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford). 2009;48:233-242.
48. Sicard P, Delemasure S, Korandji C, et al. Anti-hypertensive effects of rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic Res. 2008;42:226-236.
49. Mayer C, Gruber HJ, Landl EM, et al. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther. 2007;45:319-327.